BLOG

Patent analysis and insight

Analysis and insight to bring more predictability, transparency, and equity to your patent prosecution.

Most difficult examiners Blog Header

The Most Difficult Examiners at the USPTO (2019)

In an update to our 2016, 2017, and 2018 lists of most difficult examiners at the USPTO, we have.

Read More

USPTO Extends AFCP 2.0 Pilot Program Through September 30, 2020

The USPTO has announced its intention to extend the After Final Consideration Pilot (AFCP) 2.0.

Read More

Is Track One Still Worth It? Analysis Uncovers Five Key Trends

For patent applicants looking to move quickly, the USPTO's Track One program is a seemingly.

Read More

Beyond Allowance Rate: How to Highlight Firm Success at the USPTO

We often use allowance rate as a quick and simple way to quantify success at the USPTO -- and we.

Read More

Three Steps to Take Before You Respond to an Office Action

In the world of patent applications, timing is key. When your firm receives an office action, a.

Read More
Pfizer Mylan Header

Future of Pharma: The Pfizer / Mylan Merger

Pfizer and Mylan, the maker of EpiPens, are merging. Pfizer will offload Upjohn, its portfolio.

Read More
Claims interpretation

USPTO Guidance for Claim Interpretation

The USPTO recently hosted a webinar about the general approach to interpreting claims and how.

Read More
UT _ Raytheon

Future of Defense: The United Technologies / Raytheon Merger

United Technologies, an American multinational conglomerate, recently agreed to combine its.

Read More
cover photo

Three Steps for a Winning, Data-Backed Client Pitch

When looking for outside counsel, companies are likely hearing similar pitches from all law.

Read More
2019-patent-report

The 2019 Patent Landscape: Mid-Year Review

If the first six months of 2019 are any indication, this year will be a year of reform. 

In.

Read More

Are you ready to transform your patent practice?

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.